Ankur Chugh

Ankur Chugh

Auto-generated profile, based on publicly available information

Ankur Chugh

Department of Pediatrics Division of Pediatric Gastroenterology, Hepatology, and Nutrition Milwaukee Wisconsin USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
AFAlvin Jay Freeman
Alvin Jay Freeman
KNKenneth Ng
Kenneth Ng
FWFuchenchu Wang
Fuchenchu Wang
MAMaisam A. Abu-El-Haija
Maisam A. Abu-El-Haija
ACAnkur Chugh
Ankur Chugh
AUAliye Uc
Aliye Uc
INTRODUCTION: Among children who suffer from acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP), acute pancreatitis (AP) episodes are painful, often require hospitalization, and contribute to disease complications and progression. Despite this recognition, there are currently no interventions to prevent AP episodes. In this retrospective cohort study, we assessed the impact of pancreatic enzyme therapy (PERT) use on clinical outcomes among children with pancreatic-sufficient ARP or CP. METHODS: Children with pancreatic-sufficient ARP or CP in the INSPPIRE-2 cohort were included. Clinical outcomes were compared for those receiving vs not receiving PERT, as well as frequency of AP before and after PERT. Logistic regression was used to study the association between development of AP episodes after starting PERT and response predictors. RESULTS: Among 356 pancreatic-sufficient participants, 270 (76%) had ARP, and 60 (17%) received PERT. Among those on PERT, 42% did not have a subsequent AP episode, during a mean 2.1 years of follow-up. Children with a SPINK1 mutation (P = 0.005) and those with ARP (compared with CP, P = 0.008) were less likely to have an AP episode after starting PERT. After initiation of PERT, the mean AP annual incidence rate decreased from 3.14 down to 0.71 (P < 0.001). DISCUSSION: In a retrospective analysis, use of PERT was associated with a reduction in the incidence rate of AP among children with pancreatic-sufficient ARP or CP. These results support the need for a clinical trial to evaluate the efficacy of PERT to improve clinical outcomes among children with ARP or CP.

8 April 2024 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
RBRobert Becker
Robert Becker
MRMariah Rigsby
Mariah Rigsby
MSMariko Suchi
Mariko Suchi
DLDiana G. Lerner
Diana G. Lerner
ACAnkur Chugh
Ankur Chugh

1 December 2016 in Pediatric Annals
Verified
Journal Article
Closed access
ACAnkur Chugh
Ankur Chugh
MMMaryann Maximos
Maryann Maximos
MPMeryl Perlman
Meryl Perlman
RGRegino P. Gonzalez-Peralta
Regino P. Gonzalez-Peralta
Hepatitis is defined as inflammation of the liver. This inflammation can be acute and self-limited, chronic (leading to cirrhosis and an increased risk for hepatocellular carcinoma), or fulminant (requiring lifesaving liver transplantation). Although there are many causes of hepatitis, this article focuses on the main childhood viral hepatidities: types A, B, C, D, and E. This review discusses the main characteristics of each virus, including salient epidemiology, clinical characteristics, diagnosis, treatment, and prevention strategies. [ Pediatr Ann . 2016;45(12):e420–e426.]

1 February 2016 in Pediatric Annals
Verified
Journal Article
Closed access
JCJonathan Cordova
Jonathan Cordova
ACAnkur Chugh
Ankur Chugh
EREdgardo D. Rivera Rivera
Edgardo D. Rivera Rivera
SYSona Young
Sona Young
Pediatric inflammatory bowel disease is a chronic gastrointestinal disease consisting of Crohn's disease (CD) and ulcerative colitis (UC). Both disease processes can share similar clinical symptoms including abdominal pain, diarrhea, hematochezia, and weight loss; CD can also be complicated by penetrating and fistulizing disease. Perianal skin tags, perianal abscesses, recto-cutaneous fistulae, and rectal stenosis are among the phenotypic characteristics of perianal CD. Current treatment strategies are focused on the surgical drainage of abscesses and the closure of fistulous tracts as well as controlling intestinal inflammation with the use of immunomodulators (6-mercaptopurine and methotrexate) and biologics (infliximab and adalimumab). Current guidelines by the American Gastroenterology Association and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition recommend a combination of surgical intervention and medical management for the treatment of perianal CD. [ Pediatr Ann . 2016;45(2):e59–e62.]

11 June 2020 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
AKAmornluck Krasaelap
Amornluck Krasaelap
DLDiana Lerner
Diana Lerner
JSJames Southern
James Southern
JNJoshua Noe
Joshua Noe
ACAnkur Chugh
Ankur Chugh

1 February 2016 in Pediatric Annals
Verified
Journal Article
Closed access
EREdgardo D. Rivera Rivera
Edgardo D. Rivera Rivera
ACAnkur Chugh
Ankur Chugh
JCJonathon Cordova
Jonathon Cordova
SYSona Young
Sona Young
A 13-year-old boy with a strong family history of hereditary pancreatitis was found to have a PRSS1 mutation after being tested at age 5 years during his first documented incident of pancreatitis. Since then, a multidisciplinary team has been treating him for the diagnosis of hereditary pancreatitis. His pain episodes increased in severity over the past several months such that the pain began to severely interfere with his daily life. After extensive discussion, a total pancreatectomy with auto islet cell transplant was performed. He is now pain free and does not require any insulin. This leads us to the questions of what is hereditary pancreatitis and how is it diagnosed? What are the management and follow-up strategies needed for these patients? This article addresses these questions and informs the reader about this diagnosis and the importance of having a high index of clinical suspicion. [ Pediatr Ann . 2016;45(2):e50–e53.]